Literature DB >> 16741879

Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.

Miguel Goicoechea1, Davey M Smith, Lin Liu, Susanne May, Allan R Tenorio, Caroline C Ignacio, Alan Landay, Richard Haubrich.   

Abstract

BACKGROUND: Suboptimal CD4+ T cell recovery during antiretroviral therapy (ART) is a common clinical dilemma.
METHODS: We analyzed viral and immunologic predictors of CD4+ T cell recovery in 116 human immunodeficiency virus type 1 (HIV-1)-infected subjects who had suppressed viremia (< or = 50 copies/mL) while receiving ART. Successive measurements of T cell immunophenotypes and cellular HIV-1 DNA levels were obtained before and during receipt of ART. On the basis of increases in the CD4+ T cell count, subjects were classified as immunologically concordant (demonstrating an increase of > or = 100 CD4+ T cells/mm3) or discordant (demonstrating an increase of <100 CD4+ T cells/mm3) after 48 weeks of ART.
RESULTS: In adjusted analyses, CD4+ and CD8+ T cell activation at baseline was negatively associated with immunologic concordance at week 48 of ART (odds ratio [OR], 0.80 [P = .04] and 0.67 [P = .02], respectively). High memory (CDRA(-)CD62L-) CD8+ T cell counts at baseline (OR, 0.33 [P = .05]) predicted less CD4+ T cell recovery, whereas increased naive CD4+ T cell counts were associated with higher increases in CD4+ T cells (OR, 1.19 [P = .052]). Neither the cell-associated HIV-1 DNA level at baseline (P = .32) nor the cell-associated HIV-1 DNA level at week 48 of ART (P = .42) was associated with immunologic concordance during ART.
CONCLUSIONS: These results support the potential clinical usefulness of the baseline determination of immune activation and maturation subsets in the prediction of CD4+ T cell recovery during viral suppression. Furthermore, identification of individuals with reduced potential for CD4+ T cell recovery during ART may provide a rationale for the initiation of early therapy for some patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16741879     DOI: 10.1086/504718

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  60 in total

Review 1.  HIV and inflammation: mechanisms and consequences.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2012-06       Impact factor: 5.071

Review 2.  Role of immune activation in HIV pathogenesis.

Authors:  Peter W Hunt
Journal:  Curr HIV/AIDS Rep       Date:  2007-02       Impact factor: 5.071

3.  Case files from Stanford University Medical Center: Drug resistance testing in previously untreated patients with HIV--knowing what to look for and choosing appropriate therapy.

Authors:  Robert W Shafer; Dong Phuong Nguyen; W Jeffrey Fessel
Journal:  MedGenMed       Date:  2006-08-07

4.  Prevention of immunodeficiency virus induced CD4+ T-cell depletion by prior infection with a non-pathogenic virus.

Authors:  Julie A Terwee; Jennifer K Carlson; Wendy S Sprague; Kerry S Sondgeroth; Sarah B Shropshire; Jennifer L Troyer; Sue VandeWoude
Journal:  Virology       Date:  2008-05-22       Impact factor: 3.616

5.  Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy.

Authors:  Peter W Hunt; Huyen L Cao; Conrad Muzoora; Isaac Ssewanyana; John Bennett; Nneka Emenyonu; Annet Kembabazi; Torsten B Neilands; David R Bangsberg; Steven G Deeks; Jeffrey N Martin
Journal:  AIDS       Date:  2011-11-13       Impact factor: 4.177

6.  Delaying a treatment switch in antiretroviral-treated HIV type 1-infected patients with detectable drug-resistant viremia does not have a profound effect on immune parameters: AIDS Clinical Trials Group Study A5115.

Authors:  Allan R Tenorio; Hongyu Jiang; Yu Zheng; Barbara Bastow; Daniel R Kuritzkes; John A Bartlett; Steven G Deeks; Alan L Landay; Sharon A Riddler
Journal:  AIDS Res Hum Retroviruses       Date:  2009-02       Impact factor: 2.205

7.  Monocyte-activation phenotypes are associated with biomarkers of inflammation and coagulation in chronic HIV infection.

Authors:  Eleanor M P Wilson; Amrit Singh; Katherine Huppler Hullsiek; Dave Gibson; W Keith Henry; Ken Lichtenstein; Nur F Önen; Erna Kojic; Pragna Patel; John T Brooks; Irini Sereti; Jason V Baker
Journal:  J Infect Dis       Date:  2014-05-09       Impact factor: 5.226

8.  Gene expression before HAART initiation predicts HIV-infected individuals at risk of poor CD4+ T-cell recovery.

Authors:  Christopher H Woelk; Nadejda Beliakova-Bethell; Miguel Goicoechea; Yingdong Zhao; Pinyi Du; Steffney E Rought; Jean Lozach; Josué Pérez-Santiago; Douglas D Richman; Davey M Smith; Susan J Little
Journal:  AIDS       Date:  2010-01-16       Impact factor: 4.177

9.  Continuous improvement in the immune system of HIV-infected children on prolonged antiretroviral therapy.

Authors:  Adriana Weinberg; Ruth Dickover; Paula Britto; Chengcheng Hu; Julie Patterson-Bartlett; Joyce Kraimer; Howard Gutzman; William T Shearer; Mobeen Rathore; Ross McKinney
Journal:  AIDS       Date:  2008-11-12       Impact factor: 4.177

10.  Immune Activation While on Potent Antiretroviral Therapy Can Predict Subsequent CD4+ T-Cell Increases Through 15 Years of Treatment.

Authors:  Xinyan Zhang; Peter W Hunt; Scott M Hammer; Michelle S Cespedes; Kristine B Patterson; Ronald J Bosch
Journal:  HIV Clin Trials       Date:  2013 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.